Abe H - Search Results

1

Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.

Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K; KTK49 Liver Study Group. Atsukawa M, et al. Among authors: abe h. Hepatol Res. 2022 Mar;52(3):235-246. doi: 10.1111/hepr.13739. Epub 2021 Dec 17. Hepatol Res. 2022. PMID: 34861090

2

Expansion of CD4(+)CD25(+)FoxP3(+) regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma.

Yoshizawa K, Abe H, Kubo Y, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y. Yoshizawa K, et al. Among authors: abe h. Hepatol Res. 2010 Feb;40(2):179-87. doi: 10.1111/j.1872-034X.2009.00587.x. Epub 2010 Jan 11. Hepatol Res. 2010. PMID: 20070404

3

Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.

Aizawa Y, Yohizawa K, Aida Y, Ishiguro H, Abe H, Tsubota A. Aizawa Y, et al. Among authors: abe h. Mol Cell Biochem. 2012 Jan;360(1-2):9-14. doi: 10.1007/s11010-011-1037-5. Epub 2011 Aug 31. Mol Cell Biochem. 2012. PMID: 21879313

4

Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.

Tsubota A, Shimada N, Yoshizawa K, Furihata T, Agata R, Yumoto Y, Abe H, Ika M, Namiki Y, Chiba K, Fujise K, Tada N, Aizawa Y. Tsubota A, et al. Among authors: abe h. Liver Int. 2012 May;32(5):826-36. doi: 10.1111/j.1478-3231.2011.02727.x. Epub 2011 Dec 30. Liver Int. 2012. PMID: 22212648 Clinical Trial.

5

Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.

Tsubota A, Shimada N, Abe H, Yoshizawa K, Agata R, Yumoto Y, Ika M, Namiki Y, Nagatsuma K, Matsudaira H, Fujise K, Tada N, Aizawa Y. Tsubota A, et al. Among authors: abe h. World J Gastroenterol. 2012 Nov 7;18(41):5879-88. doi: 10.3748/wjg.v18.i41.5879. World J Gastroenterol. 2012. PMID: 23139603 Free PMC article. Clinical Trial.

6

New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.

Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y. Abe H, et al. J Med Virol. 2013 Sep;85(9):1523-33. doi: 10.1002/jmv.23626. Epub 2013 Jun 17. J Med Virol. 2013. PMID: 23775277

7

Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.

Yoshizawa K, Abe H, Aida Y, Ishiguro H, Ika M, Shimada N, Tsubota A, Aizawa Y. Yoshizawa K, et al. Among authors: abe h. J Med Virol. 2013 Jul;85(7):1180-90. doi: 10.1002/jmv.23597. J Med Virol. 2013. PMID: 23918536

8

Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection.

Aizawa Y, Shimada N, Abe H, Seki N, Aida Y, Ishiguro H, Ika M, Kato K, Tsubota A. Aizawa Y, et al. Among authors: abe h. Hepat Mon. 2013 May 27;13(5):e8988. doi: 10.5812/hepatmon.8988. eCollection 2013 May. Hepat Mon. 2013. PMID: 23967025 Free PMC article.

9

Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.

Tsubota A, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y. Tsubota A, et al. Among authors: abe h. J Gastroenterol Hepatol. 2014 Jan;29(1):144-50. doi: 10.1111/jgh.12402. J Gastroenterol Hepatol. 2014. PMID: 24117654

10

α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype.

Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y. Shimada N, et al. Among authors: abe h. J Med Virol. 2014 Mar;86(3):461-72. doi: 10.1002/jmv.23824. Epub 2013 Oct 28. J Med Virol. 2014. PMID: 24166425

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,225 results

Search Page